Watch GOSS. Know when insiders buy.
One email the day a filing lands. Free.
GOSS
Gossamer Bio, Inc.
9.79
+0.21 +2.19%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
63
WATCH · shorts 63
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.8BP/E —DIV YIELD —FCF YIELD -3.40%REV TTM $53.3M +32.4%NET INCOME −$125.2MNET CASH $12.6M52W 8.43 – 303.20SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $9.2M | −19.6% | — | −$26.1M | $16.9M | — | -0.08 | −$39.4M | $0 | −$39.4M | Aug 13 |
| Q1 2026 · Mar 31 | $17M | +71.5% | — | −$44.9M | −$46.7M | — | -0.20 | −$38.7M | $0 | −$38.7M | Aug 13 |
| Q4 2025 · Dec 31derived | $13.8M | +47.1% | — | −$46M | −$47.2M | — | -0.21 | −$48.3M | $0 | −$48.3M | Mar 17 |
| Q3 2025 · Sep 30 | $13.3M | +40.2% | — | −$49.1M | −$48.2M | — | -0.21 | −$36.2M | $0 | −$36.2M | Nov 5 |
| Q2 2025 · Jun 30 | $11.5M | −88.0% | — | −$38.8M | −$38.3M | −177.7% | -0.17 | −$47.1M | $53K | −$47.1M | Aug 13 |
| Q1 2025 · Mar 31 | $9.9M | — | — | −$36.8M | −$36.6M | — | -0.16 | −$39.7M | $26K | −$39.8M | Aug 13 |
| Q4 2024 · Dec 31derived | $9.4M | — | — | −$36.1M | −$33M | — | -0.15 | −$35.5M | $0 | −$35.5M | Mar 17 |
| Q3 2024 · Sep 30 | $9.5M | — | — | −$33.9M | −$30.8M | — | -0.14 | −$32M | $0 | −$32M | Nov 5 |
| Q2 2024 · Jun 30 | $95.8M | — | — | $52.1M | $49.2M | — | 0.22 | $116.3M | $0 | $116.3M | Nov 5 |
| Q1 2024 · Mar 31 | $0 | — | — | −$42M | −$41.9M | — | -0.19 | −$52.3M | $0 | −$52.3M | Nov 5 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$49M | −$48.1M | — | -0.15 | −$33.4M | $0 | −$33.4M | Mar 17 |
| Q3 2023 · Sep 30 | $0 | — | — | −$40.5M | −$40M | — | -0.21 | −$34.5M | $0 | −$34.5M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $48.5M | — | −$170.7M | −$170.4M | -351.5% | -0.75 | −$171.3M | $79K | −$171.3M | — | — |
| FY2024 · to Dec 31 | $114.7M | — | −$59.9M | −$56.5M | -49.3% | -0.25 | −$3.5M | $0 | −$3.5M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$183.8M | −$179.8M | — | -1.18 | −$159.2M | $0 | −$159.2M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$218.6M | −$229.4M | — | -2.71 | −$187M | $410K | −$187.4M | — | — |
| FY2021 · to Dec 31 | — | — | −$216.1M | −$234M | — | -3.13 | −$188.9M | $1.5M | −$190.4M | — | — |
| FY2020 · to Dec 31 | — | — | −$234M | −$243.4M | — | -3.55 | −$176.4M | $1.5M | −$177.9M | — | — |
Every number comes from Gossamer Bio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.